Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
--Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today reported financial ...
Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
PLYMOUTH MEETING, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and ...
Prader-Willi Syndrome (PWS) Phase 2 Proof-Of-Concept Study Topline Data Showed Positive Signal in Treating Excessive Daytime Sleepiness Good Momentum in Phase 3 Idiopathic Hypersomnia (IH) INTUNE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results